Sanofi gets dengue vax approved in Mexico; Glaxo hit with class action suit over nausea treatment Zofran;

@FiercePharma: Allergy Therapeutics brings long-delayed grass allergy vax into PhII. FierceVaccines story | Follow @FiercePharma

@CarlyHFierce: ICYMI: AbbVie's Imbruvica, Amgen's Kyprolis shine at annual ASH meeting. More | Follow @CarlyHFierce

> On Wednesday, Mexico approved Sanofi's ($SNY) dengue vaccine, the first to treat the mosquito-borne virus. Story

> A class action lawsuit has been filed in Canada against GlaxoSmithKline ($GSK) by women who claim their children were harmed when they received Zofran, a drug they say is commonly prescribed off label for treating nausea during pregnancy. Story

> AstraZeneca's ($AZN) lung cancer treatment Tagrisso has become the fourth med to be made available to U.K. patients before approval under an early access scheme. Report

> Johnson & Johnson's ($JNJ) Janssen has submitted an application to the EMA for use of Stelara in adults with severe active Crohn's disease. Report

Medical Device News

@FierceMedDev: Scientists roll out 3-D printed self-assembling blood vessels. Article | Follow @FierceMedDev

@EmilyWFierce: Pharma ad budgets stay flat, even as spending jumps across the board: Report. FiercePharmaMarketing story | Follow @EmilyWFierce

> Illumina Accelerator discloses its latest funded class of four genomic startups. Story

> Top gynecologists push back at FDA crackdown on power morcellator devices. Report

> Chemotherapy cooling cap to reduce hair loss for breast cancer patients gets FDA nod. Article

Biotech News

@FierceBiotech: Dana-Farber researchers highlight progress with new drugs for acute myeloid leukemia. FierceBiotechResearch article | Follow @FierceBiotech

@JohnCFierce: Eyeing pivotal PhIIIs, Margolin nabs $53M crossover round for Allena. News | Follow @JohnCFierce

@DamianFierce: "You know, at the right price these guys basically will do anything." More from Bloomberg | Follow @DamianFierce

> Rubius goes after genetically re-engineered red-cell drugs with $25M from Flagship. Report

> Cara's oral opioid cuts osteoarthritis pain in a Phase II trial. Story

> Baxalta wins FDA approval with a treatment for a rare bleeding disease. Article

Biotech Research News

> New screening tech at Scripps spotlights diabetes drug candidates. Item

> Dana-Farber researchers highlight progress with new drugs for acute myeloid leukemia. More

> Imperial College scientists engineer a CRISPR/Cas9 breakthrough on malaria. Report

> Florida U team's gene therapy safeguards cognition in rats. Story

> Epilepsy scientific meeting highlights promise of cannabidiol for reducing seizures. Article

Pharma Marketing News

> Can new PhIII data help Gilead's Zydelig stage a comeback in CLL? Article

> Pharma ad budgets stay flat, even as spending jumps across the board: Report. More

> Gilead's Harvoni beats Sovaldi, AbbVie's Viekira Pak in hep C drug safety: Advera. Story

> Cancer-free President Carter notes Keytruda treatment: Will the celebrity effect kick in? More

> With Paris spotlight on climate change, here's how Big Pharma stacks up. Article

Vaccines News

> Second flu shot helps cancer patients stave off infection, Yale team says. Item

> Japan's Kaketsuken covered up illicit blood product, vaccine production methods for 40 years. More

> Cerberus Capital management invests $105M in PaxVax. Report

> Allergy Therapeutics brings long-delayed grass allergy vax into PhII. Story

> U.S. Army, Hawaii Biotech join for dengue vaccine effort. Article

And Finally... The acute myeloid leukemia (AML) drug market will expand to $932.6 million by 2024 from $342.7 million in 2014, research and consulting firm GlobalData says. More

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.